为对抗IgLON5疾病的临床评估开发综合评分

Carles Gaig¹, Thomas Grüter¹, Anna Heidbreder¹+7

• ¹From the Neuroimmunology Program (C.G., L.S., A.I., J.S., J.O.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Department of Neurology (C.G., A.I., J.S., J.O.D.), and Sleep Disorders Center (C.G., A.I., J.S.), Hospital Clinic, Barcelona, Spain; Department of Neurology (T.G., I.A.), St. Josef Hospital, Ruhr University Bochum; Department Neurology (A.H.), Division of Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Germany; Department of Neurology (A.H.), Medical University of Innsbruck; Department of Neurology (A.H.), Kepler Universitätsklinikum, Linz, Austria; Neuroimmunology (F.L.), Institute of Clinical Chemistry and Department of Neurology, University Hospital Schleswig-Holstein and Kiel University, Germany; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.O.D.), Barcelona, Spain.